European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 105, Issue 2 , Pages 161-165 , 15 November 2002

Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects

Received 20 November 2001 ,Revised 11 April 2002 ,Accepted 26 April 2002.

References 

  1. Quinn MA. Hormonal treatment of endometrial cancer. Hematol. Oncol. Clin. North Am. 1999;13:163–187
  2. Emons G, Heyl W. Hormonal treatment of endometrial cancer. J. Cancer Res. Clin. Oncol. 2000;126:619–623
  3. Kim YB, Holschneider CH, Ghosh K, et al.  Progestin alone as primary treatment of endometrial carcinoma in pre-menopausal women. Cancer. 1997;79:320–327
  4. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet. Gynecol. 1997;90:434–440
  5. Macdonald RR, Thorogood J, Mason MK. A randomized trial of progestogens in the primary treatment of endometrial carcinoma. Br. J. Obstet. Gynaecol. 1988;95:166–174
  6. Johnston SRD, Smith IE, Dowsett M. Place of aromatase inhibitors in the endocrine therapy of breast cancer. In: Miller WR, Santen RJ, editors. Aromatase inhibition and breast cancer. New York: Marcel Dekker Inc., 2001. p. 29–50.
  7. Miller WR, Santen RJ, editors. Aromatase inhibition and breast cancer. New York: Marcel Dekker Inc., 2001.
  8. Sasano H, Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev. 1998;19:593–607
  9. Dilman VM. Endocrinologic oncology. Leningrad: Meditsina, 1983.
  10. Bokhman JV. Handbook on gynecological oncology. Leningrad: Meditsina, 1989.
  11. Gusberg SB. Estrogen and endometrial cancer: an epilogue a la recherche du temps perdu. Gynecol Oncol. 1994;52:3–9
  12. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295–308
  13. Weiderpass E, Adami HO, Baron JA, et al.  Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91:1131–1137
  14. Bulun SE, Economos K, Miller D, Simpson ER. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab. 1994;79:1831–1834
  15. Berstein LM. Extragonadal estrogens production (role in physiology and pathology). St. Petersburg: Nauka Publishers, 1998.
  16. Berstein LM, Kovalevskij AJ, Larionov AA, Maximov SJ. Aromatase in normal and malignant endometrium. Akush Gynecol. 2001;4:3–7
  17. Rose PG, Brunetto VL, VanLe L, Bell J, Walker J, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;78:212–216
  18. Saez M, Martin P, Chouvet CD. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Res. 1978;38:3468–3473
  19. Tilson-Mallett N, Santner SJ, Feil PD, Santen RJ. Biological significance of aromatase activity in human breast tumors. J Clin Endocrinol Metab. 1983;57:1125–1128
  20. Berstein L, Gerschanovitch M, Gamaynova V, Loskutova G, Tsyrlina E. Short-term letrozole effect on blood estrogens level in normal weight and obese endometrial cancer patients. In: Proceedings of the Third Internatational Conference on Aromatase and Its Inhibitors: New Biology and Clinical Perspectives. Prague, 1998: p. 32
  21. Bokhman JV. Two pathogenic types of endometrial carcinoma. Gynecol. Oncol. 1983;15:10–17

PII: S0301-2115(02)00147-1

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 105, Issue 2 , Pages 161-165 , 15 November 2002

Article Tools